It’s a small sample, but dare we hope?

A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease, as it virtually cured it in every member of a clinical trial.

 

Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial sponsored by pharma giant GlaxoSmithKline (GSK).

 

A year after the trial’s completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of the cancer in their body.